Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event: Results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide

European Journal of Haematology

Volumn 96, Issue 1, 2016, Pages 98-106

  Schwarz, Jiří ^a,b   Ovesná, Petra ^c   Černá, Olga ^d   Kissová, Jarmila ^e   Soukupová, Jacqueline Maaloufová ^a   Brychtová, Yvona ^e   Doubek, Michael ^e   Červinek, Libor ^e   Cmunt, Eduard ^b   Dulíček, Petr ^f   Campr, Vít ^a,g   Křen, Leoš ^e   Penka, Miroslav ^e   Michiels, J J ^h   Petrides, P E ^h   Markova J ^h  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^h NONE

Author keywords

JAK2; Anagrelide; Myeloproliferative disorders; Platelets; Thrombophilia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; HOMOCYSTEINE; JANUS KINASE 2; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN; TRIACYLGLYCEROL; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDD CHIARI SYNDROME; CHILD; COHORT ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; GROUPS BY AGE; HEMATOCRIT; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; LIENAL VEIN THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; MULTICENTER STUDY; MYELOPROLIFERATIVE DISORDER; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; SMOKING; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; AMINO ACID SUBSTITUTION; BLOOD; COMPLICATION; GENETICS; MISSENSE MUTATION; PHILADELPHIA 1 CHROMOSOME; REGISTER; RISK FACTOR; THROMBOCYTOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; ASPIRIN; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; JANUS KINASE 2; MALE; MUTATION, MISSENSE; PHILADELPHIA CHROMOSOME; PLATELET COUNT; PROSPECTIVE STUDIES; QUINAZOLINES; REGISTRIES; RISK FACTORS; THROMBOCYTOSIS; THROMBOSIS;

EID: 84955193963     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12554     Document Type: Article

References (43)

1. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39.
2. Tefferi A, Thiele J, Orazi A, etal. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
3. Michiels JJ, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera, and idiopathic myelofibrosis (agnogenic myeloid metaplasia). Int J Hematol 2002;76:133-45.
4. Schwarz J, Penka M, Campr V, etal. Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases - principles and rationale of CZEMP recommendations. [In Czech with extensive English abstract]. Vnitř Lék 2011;57:189-213.
5. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-52.
6. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M, Mazzucconi MG, Rodeghiero F, Tura S. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32.
7. Harrison CN, Bareford D, Butt N, etal. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol 2010;149:352-75.
8. Barbui T, Barosi G, Birgegard G, etal. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-70.
9. Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulíček P, Campr V, Křen L, Penka M. Analysis of risk factors: the rationale of the guidelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia. Semin Thromb Hemost 2006;32:231-45.
10. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990;8:556-62.
11. Barbui T, Finazzi G, Carobbio A, etal. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 2012;120:5128-33.
12. Besses C, Cervantes F, Pereira A, Florensa L, Solé F, Hernández-Boluda JC, Woessner S, Sans-Sabrafen J, Rozman C, Montserrat E. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999;13:150-4.
13. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-3.
14. Budde U, Schaefer G, Mueller N, Egli H, Dent J, Ruggeri Z, Zimmerman T. Acquired von Willebrand's disease in the myeloproliferative syndrome. Blood 1984;64:981-5.
15. van Genderen PJJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996;22(Suppl. 1):79-82.
16. Michiels JJ, Berneman ZN, Schroyens W, van Vliet HHDM. Pathophysiology and treatment of platelet-mediated microvascular disturbances, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets 2004;15:67-84.
17. Michiels JJ, Kutti J, Stark P, etal. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 1999;54:46-62.
18. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
19. Carobbio A, Antonioli E, Guglielmelli P, Vannucchi AM, Delaini F, Guerini V, Finazzi G, Rambaldi A, Barbui T. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008;26:2732-6.
20. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
21. Schwarz J, Penka M, Indrák K, Pospíšilová D, Pytlík R, Dulíček P, Doubek M, Křen L, Campr V. The WHO 2008 classification of Ph- myeloproliferative disorders: statement of the Czech MPD Working Group. Leukemia 2008;22:2118-9.
22. Penka M, Schwarz J, Pytlík R, Doubek M, Brychtová Y, Dulíček P. Practice guidelines for diagnosis and therapy of essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases. [In Czech with English abstract]. Vnitř Lék 2005;51:741-51.
23. Marková J, Průková D, Volková Z, Schwarz J. A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2 V617F mutation. Leuk Lymphoma 2007;48:636-9.
24. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E, Gisslinger H. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile. Cancer 2004;101:2239-46.
25. Michiels JJ, Abels J, Steketee J, van Vliet HHDM, Vuzevski VD. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 1985;102:466-71.
26. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HHDM. Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 1993;43:1107-10.
27. Dawson AA, Ogston D. The influence of the platelet count on the incidence of thrombotic and haemorrhagic complications in polycythaemia vera. Postgrad Med J 1970;46:76-8.
28. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka HM, Kralovics R, Petrides PE. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 2013;121:1720-8.
29. Harrison CN, Campbell PJ, Buck G, etal. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
30. 9/L be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br J Haematol 1998;100:15-23.
31. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-14.
32. Arellano-Rodrigo E, Alvarez-Larrán A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006;91:169-75.
33. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33:523-30.
34. Cervantes F, Arellano-Rodrigo E, Alvarez-Larrán A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009;94:1484-8.
35. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.
36. Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996;52:14-20.
37. Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, Iannaccone L, Annunziata M, Ferrara F, Brancaccio V, Balzano A. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease. Am J Hematol 2003;72:75-81.
38. Gisslinger H, Müllner M, Pabinger I, Heis-Vahidi-Fard N, Gisslinger B, Brichta A, Bachleitner-Hofmann T, Mannhalter C. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica 2005;90:408-10.
39. Kessler CM. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders. Semin Hematol 2004;41(Suppl. 3):10-4.
40. Ruggeri M, Gisslinger H, Tosetto A, etal. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6.
41. Trifa AP, Cucuianu A, Popp RA, Coada CA, Costache RM, Militaru MS, Vesa SC, Pop IV. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. Ann Hematol 2014;93:203-9.
42. Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol 2013;160:177-87.
43. Penka M, Schwarz J, Campr V, etal. Summary of recommendations for the diagnosis and therapy of BCR/ABL-negative myeloproliferation of the Czech Working Group for Ph-negative myeloproliferative disease (CZEMP) of the Czech Hematologic Society of CLS JEP. [In Czech with English abstract]. Vnitř Lék 2012;58:163-8.